<div id="readability-page-1"><p>Lake Street analyst Chad Messer reiterated a Buy rating on Bolt Biotherapeutics today and set a price target of $75.00.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>According to TipRanks, Messer is an analyst with an average return of <span>-0.3%</span> and a 38.73% success rate. Messer covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Oncolytics Biotech, and Bolt Biotherapeutics.</p> <p>The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bolt Biotherapeutics with a $29.33 average price target.</p></div>

BOLT

<p>Lake Street analyst Chad Messer reiterated a Buy rating for Bolt Biotherapeutics, setting a price target of $75. The analyst has an average return of -0.3% and a 38.73% success rate. The general consensus on The Street is a Moderate Buy with a $29.33 average price target for Bolt Biotherapeutics.</p>

Bolt Biotherapeutics (BOLT) Gets a Buy from Lake Street